Skip to content
AwardedDNKGoods

Rammeaftale om køb af Breyanzi (lisocabtagene maraleucel)

Published
Published 15 May 2025

Overview

Formålet med rammeaftalen er at kunne forsyne sygehusapotekerne hos Amgros' interessenter med lægemidlet Breyanzi (lisocabtagene maraleucel). Region Hovedstadens sygehusapotek foretager endvidere indkøb med henblik på videresalg Grønland og Færøerne.

Key details

Country
DNK
Status
Awarded
Category
Goods
Procedure
Direct
Published
15 May 2025
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
DKK 1
Award date
15 August 2025
Contract period
15 August 2025 → 31 July 2029
Winner
  • Bristol-Myers Squibb Denmark. Filial Af Bristol-Myers Squibb AB. Sverige

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    9 March 2026

  2. Contract Notice

    15 May 2025

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Rammeaftale om køb af Breyanzi (lisocabtagene maraleucel) — won by Bristol-Myers Squibb Denmark. Filial Af Bristol-Myers Squibb AB. Sverige — Skim